2003
DOI: 10.1016/s1044-7431(02)00032-5
|View full text |Cite
|
Sign up to set email alerts
|

Suppression of Rho-kinase activity promotes axonal growth on inhibitory CNS substrates

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

6
139
0

Year Published

2003
2003
2019
2019

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 195 publications
(145 citation statements)
references
References 50 publications
6
139
0
Order By: Relevance
“…Accordingly, human hemizygosity of LIM-domain-containing protein kinase (LIMK), which is activated by p21-activated kinase (PAK), an effector of Rac GTPase, has been associated with MR (23). On the other hand, Rho activation has been shown to cause neurite retraction (39,40) by means of formation of stress fibers in the growth cone (41) and to reduce growth cone mobility and dendrite branching (42,43). The meaning of these latter actions in the physiology of learning is unclear.…”
Section: Discussionmentioning
confidence: 99%
“…Accordingly, human hemizygosity of LIM-domain-containing protein kinase (LIMK), which is activated by p21-activated kinase (PAK), an effector of Rac GTPase, has been associated with MR (23). On the other hand, Rho activation has been shown to cause neurite retraction (39,40) by means of formation of stress fibers in the growth cone (41) and to reduce growth cone mobility and dendrite branching (42,43). The meaning of these latter actions in the physiology of learning is unclear.…”
Section: Discussionmentioning
confidence: 99%
“…However, activation of the small GTPase RhoA appears to be a necessary step in mediating CSPG-associated inhibition in vitro. Several studies have reported disinhibition of neurite outgrowth on CSPG-rich substrates in the presence of ROCK inhibitors [54,55]. Therefore, blockade of the Rho/ROCK axis holds the potential to block signaling by myelin and CSPGs.…”
Section: Astroglial Scars and Cspgsmentioning
confidence: 99%
“…HA1077 is in clinical use for managing cerebral vasospasm associated with subarachnoid hemorrhage and is under clinical trial for acute ischemic stroke [37], among other conditions. Application of Y27632 has also been investigated for promotion of neurite outgrowth and axonal regeneration [38][39][40][41][42][43][44][45] and inactivation of Rho or ROCK signaling promoted functional recovery and/or axonal regeneration after neural injuries [46][47][48].…”
Section: Introductionmentioning
confidence: 99%